Evidence map›Paper›PMID 36686783›Full record

ArticleFrontiers in oncology2022

Investigation of the prevalence and clinical implications of

Yanhong Shang, Jianming Mo, Ran Huo, Xiaofang Li, Guotao Fang, Zichun Wei, Guomin Gu, Xiaodan Zhu, Chan Zhang, Chunling Liu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yanhong ShangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, China.
Jianming MoDepartment of Pulmonary and Critical Care Medicine, Peking University Shenzhen Hospital, Shenzhen, China.
Ran HuoDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, China.
Xiaofang LiDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, China.
Guotao FangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, China.
Zichun WeiThoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, China.
Guomin GuSecond Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Xiaodan ZhuSecond Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Chan ZhangDepartment of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Chunling LiuDepartment of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical, Urumqi, China.
Dong YanDepartment of Oncology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Affiliated Hospital of Hebei University · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CNPeking University Shenzhen Hospital · CNXinjiang Medical University · CNSecond Affiliated Hospital of Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although rare, Methods: We retrospectively screened 40996 patients, spanning 19 cancer types, who had available genomic profiles acquired with DNA-based next-generation sequencing (NGS). We characterized the clinical and molecular features of the Results: A total of 22 patients were detected with Conclusions: Our study identified an overall

Indexed as

deltaHER2ERBB2ERBB2delta16exon 16 skippinglung cancer

Identifiers

PMID36686783
PMCPMC9859631
OpenAlexW4313639815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.